Relationship between intradermal tumor suppression and tumor immunity

Area of Science:

• Immunology
• Oncology
• Dermatology

Background:

• Tumor growth can be suppressed by immune stimulants.
• The route of administration for these stimulants may impact efficacy.

Purpose of the Study:

• To compare the efficacy of intradermal (ID) versus other injection sites for tumor growth suppression using immune stimulants.
• To investigate the role of local versus systemic tumor immunity in the observed suppression.

Main Methods:

• Three tumor-immune stimulant mixtures (LSTRA-BCG, 13762A-BCG, CaD2-Corynebacterium parvum) were injected intradermally (ID), subcutaneously (SC), intraperitoneally (IP), or intravenously (IV).
• Tumor growth suppression was assessed at different injection sites.
• Tumor challenge models were used to evaluate afferent and efferent immune responses.

Main Results:

• Intradermal injection was superior to subcutaneous injection for suppressing tumor growth across tested mixtures.
• Intraperitoneal or intravenous administration of LSTRA-BCG showed reduced efficacy compared to ID.
• In the LSTRA-BCG model, the ID site was not uniquely superior for afferent or efferent immune responses; other sites were equally effective.

Conclusions:

• Local administration of tumor-immune stimulant mixtures in the skin (intradermal) is frequently more effective for tumor suppression than other sites.
• Local tumor suppression does not appear to depend primarily on systemic tumor immunity.
• Both afferent and efferent tumor immunity were equally efficient via the four routes tested.